Biopharmaceuticals News

Recent industry report about Biopharmaceuticals company news, including latest market trends and industry updates in 2024. This sector news is compiled by Mordor Intelligence™ Biopharmaceuticals Market industry experts.

Biopharmaceuticals News

  • July 2023: Pfizer invested USD 25 million in Caribou Biosciences to progress an immune-cloaked allogeneic CAR-T cell therapy, CB-011. The company is currently evaluating the cell therapy in a Phase I CaMMouflage clinical trial for relapsed or refractory multiple myeloma.
  • April 2023: InflaRx N.V.'s Gohibic (vilobelimab), a first-in-class monoclonal anti-human complement factor C5a antibody, was granted an Emergency Use Authorization by the United States Food and Drug Administration for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation, or extracorporeal membrane oxygenation.
download-icon Get full market coverage in this industry
Download Sample
  • March 2023: Assentia launched tech platforms to support payments in the clinical trial space. The company released two SaaS-based applications, GrantPay and GrantPact, to provide clinical trial contract negotiation and payment services.
  • February 2023: Vial partnered with Egnyte. By integrating Egnyte's eTMF, Vial will be able to offer clients the gold standard in eTMF management, compliance, and audit readiness with the increased bar in clinical trial technology.
  • November 2023: QIAGEN NV launched the Microbiome WGS (whole-genome sequencing) SeqSets which is a comprehensive Sample to Insight workflow designed to provide an easy-to-use solution that maximizes efficiency and reproducibility in microbiome research. 
  • June 2023: Zymo Research launched its full-length 16S sequencing service offering researchers high-quality, full-length 16S rRNA gene sequencing for microbiome analysis.
  • In July 2022, SynbiCITE, the National Centre for the Industrial Translation of Synthetic Biology in the United Kingdom, received a grant of USD 6.6 million (GBP 5.5 million) from SynBioVen. The funding would enable the Imperial-hosted center to continue to support synthetic biology startups and small and medium enterprises, strengthen the emerging economy of the United Kingdom, and unlock the societal benefits of synthetic biology.
  • In January 2022, Ribbon Biolabs, a DNA synthesis company, raised USD 19.12 million (EUR 18 million) in a series A financing fund. The company enabled commercial-scale production facilities and the United States expansion for DNA synthesis technology with this fund.
  • In August 2022, Applied StemCell, Inc. (ASC), a cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry for their needs in developing and manufacturing cell and gene products, expanded its Current Good Manufacturing (cGMP) facility. ASC has successfully carried out cell banking and product manufacturing projects in its current cGMP suite and is now set on building 4 additional cGMP cleanrooms, cryo-storage space, process development, and QC/QA space.
  • In January 2022, stem cell manufacturing startup Cellino Biotech raised a USD 80 million Series A financing round led by Leaps by Bayer along with 8VC, Humboldt Fund, and new investors including Felicis Ventures and Khosla Ventures, that could fix a problem holding the biotech industry back. Cellino plans to expand access to stem cell-based therapies with the goal to build the first autonomous human cell foundry in 2025.
  • Dec 2022: ArcticZymes Technologies (AZT) upscaled the production of ArcticZymes Proteinase. In addition, the company launched a glycerol-free formulation of the proteinase that enables the company to support customers requiring a lyophilization-compatible formulation of the proteinase for use in high-throughput molecular diagnostic workflows.
  • Oct 2020: A team of biochemists from Chulalongkorn University became the first researchers in Thailand to study proteolytic enzymes (proteinase K) for the COVID-19 virus at a molecular level in 3D, possibly leading to the development of COVID-19 treatments.
  • Feb 2021: Novacyt launched its SNPsig portfolio of PCR genotyping assays that can be used to aid the diagnosis of new variants of SARS-CoV-2.
  • Aug 2021: Thermo Fisher Scientific expanded its production capability. The company updated its Applied Biosystems TaqMan SARS-CoV-2 mutation panel for the diagnosis of the Delta and Lambda strains. The panel enables laboratories to track known mutations by selecting from a menu of over 50 assays designed to screen for different variants.
  • In August 2022, Trivitron Healthcare launched the Center of Excellence with state- of- the art R&D and manufacturing facilities in India. This center will implement research and innovation in the field of genomics and others.
  • In July 2022, Replay launched with USD 55 million in seed financing to transform genomic medicine with interlinking technology platforms. The launch is supported by an international syndicate f investors that include KKR, OMX ventures, ARTIS Ventures, and Landsdowne Partners.
  • October 2022: Verge Genomics, a clinical-stage and technology-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced dosing the first subject in its Phase 1 clinical trial of VRG50635.
  • October 2022: NGM Bio released topline results from the CATALINA Phase 2 Trial of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration.
  • May 2022: Invitae launched the expanded Invitae Pharmacogenomics (PGx) Panel, which includes the specialized Invitae Pharmacogenomics Mental Health Panel and access to a clinical decision support tool (CDST).
  • March 2022: Day-Lewis declared their plan to launch a private pharmacogenomic testing service in a community pharmacy.
  • December 2021: Guerbet and Bracco Imaging announced a global collaboration for Gadopiclenol, a next-generation magnetic resonance imaging (MRI) contrast agent.
  • December 2021: Qaelum NV announced a strategic partnership with Ulrich GmbH & Co. KG in Ulm to combine their advanced Contrast Management solution with the contrast media injectors of Ulrich Medical to support the needs of hospitals and imaging networks.

Biopharmaceutical Industry Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)